Меню
Идёт набор NCT05295615

Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

Без фазы С лечением Alzheimer Disease

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: ECHS AD Device.
Кому может быть актуально
Состояния в реестре: Alzheimer Disease. Базовые параметры: 50 лет — 100 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Effects of PEMF Treatment on Patients With Mild to Moderate Alzheimer's Disease in a Controlled Pilot Study

Обзор

An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end points are the The Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Mini-Mental State Exam. Participants will be followed-up for 9 months post-treatment.

Вмешательства

  • Устройство ECHS AD Device
    Pulsed electromagnetic therapy device

Первичные конечные точки

  • The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) [Срок оценки: Change between day 0, and 30, 60, 90, 120, 150, 240, 310, 400 days]
  • Mini-Mental Status Exam (MMSE) [Срок оценки: Change between day 0, and 30, 60, 90, 120, 150, 240, 310, 400 days]
  • Global Deterioration questionnaire [Срок оценки: Change between day 0, and 30, 60, 90, 120, 150, 240, 310, 400 days]
  • Quality of Life Scale [Срок оценки: Change between day 0, and 30, 60, 90, 120, 150, 240, 310, 400 days]

Критерии участия

Критерии включения

  • Age ≥ 50 years
  • Patients diagnosed with mild to moderate Alzheimer's Dementia defi
  • At least an eighth grade of educational achievement
  • If female, post-menopausal.
  • MMSE score between 16 and 26
  • Capable of providing consent or having a surrogate (e.g., spouse, family member) capable of providing consent if participant lacks consent capacity
  • Able and willing to comply with the protocol
  • If the participant is receiving a cholinesterase inhibitor and/or memantine, such medication has been prescribed for at least 3 months prior to screening and the dose is stable for at least 60 days prior to screening (that dose needs to be maintained throughout the period of this study)
  • Spouse, family member or professional caregiver agree and are capable of taking care of the participation of the patient in the study (answering questions regarding the patient's condition, assuming responsibility for medication, and applying and supervising the daily PEMF treatments)
  • Physical clearance for study participation as evaluated by the clinician

Критерии исключения

  • The patient lacks capacity to consent to study participation and no surrogate is available to provide consent
  • History of epileptic seizures or epilepsy
  • Currently taking medication that lowers the seizure threshold
  • Presence of depression, bipolar disorder, a psychotic disorder, or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
  • Severe agitation that would interfere with study procedures
  • Alcoholism or substance use disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation
  • Major surgery (defined as any major abdominal, vascular or thoracic surgery requiring general anesthesia and resulting in a period of >1 week hospitalization) within 4 weeks
  • Head anatomy that interferes with the fit of the treatment device
  • Participation in another clinical trial within the previous 30 days
  • Metal implants in the head, (i.e., cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

США · 1 центр
  • Hackensack Medical Center — Hackensack

Идентификаторы

NCT: NCT05295615 · HM003

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗